MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 463239 | Name: PF00835231
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PF-00835231 is a potent inhibitor of the SARS-CoV-1 3CL protease (3CL^pro), the main protease critical for viral replication. In biochemical assays, PF-00835231 demonstrated high affinity for the SARS-CoV-1 3CL^pro with a Ki of 0.27 nM, indicating tight binding and effective enzymatic inhibition. Additionally, PF-00835231 exhibits antiviral activity in cell-based assays, with EC<sub>50</sub> values in the low micromolar to submicromolar range, depending on the cell type and assay conditions. The compound shows good selectivity for viral 3CL^pro over human proteases, which is critical for minimizing off-target effects. Its pharmacokinetic profile and in vitro potency supported its advancement as a lead compound during early coronavirus antiviral development efforts.

Chemical Structure

PF00835231
PF00835231
CAS#870153-29-0

Theoretical Analysis

MedKoo Cat#: 463239

Name: PF00835231

CAS#: 870153-29-0

Chemical Formula: C24H32N4O6

Exact Mass: 472.2322

Molecular Weight: 472.54

Elemental Analysis: C, 61.00; H, 6.83; N, 11.86; O, 20.31

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
870153-29-0 70153-89-2 (racemic) 870153-90-5 870153-91-6
Synonym
PF 00835231; PF-00835231; PF00835231; PF 835231; PF-835231; PF835231;
IUPAC/Chemical Name
N-((S)-1-(((S)-4-hydroxy-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-methoxy-1H-indole-2-carboxamide
InChi Key
QDIMHKWNHMVDJB-WBAXXEDZSA-N
InChi Code
InChI=1S/C24H32N4O6/c1-13(2)9-18(23(32)27-17(20(30)12-29)10-14-7-8-25-22(14)31)28-24(33)19-11-15-16(26-19)5-4-6-21(15)34-3/h4-6,11,13-14,17-18,26,29H,7-10,12H2,1-3H3,(H,25,31)(H,27,32)(H,28,33)/t14-,17-,18-/m0/s1
SMILES Code
OCC([C@H](C[C@@H]1CCNC1=O)NC([C@H](CC(C)C)NC(C2=CC3=C(OC)C=CC=C3N2)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 472.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhou X, Lu X, Lin C, Zou X, Li W, Zeng X, Wang J, Zeng P, Wang W, Zhang J, Jiang H, Li J. Structural basis for the inhibition of coronaviral main proteases by PF-00835231. Acta Biochim Biophys Sin (Shanghai). 2024 Jul 29. doi: 10.3724/abbs.2024122. Epub ahead of print. PMID: 39076076. 2: Grosicki M, Wojnar-Lason K, Mosiolek S, Mateuszuk L, Stojak M, Chlopicki S. Distinct profile of antiviral drugs effects in aortic and pulmonary endothelial cells revealed by high-content microscopy and cell painting assays. Toxicol Appl Pharmacol. 2024 Sep;490:117030. doi: 10.1016/j.taap.2024.117030. Epub 2024 Jul 7. PMID: 38981531. 3: Robinson P, Toussi SS, Aggarwal S, Bergman A, Zhu T, Hackman F, Sathish JG, Updyke L, Loudon P, Krishna G, Clevenbergh P, Hernandez-Mora MG, Cisneros Herreros JM, Albertson TE, Dougan M, Thacker A, Baniecki ML, Soares H, Whitlock M, Nucci G, Menon S, Anderson AS, Binks M. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19. Open Forum Infect Dis. 2023 Jul 10;10(8):ofad355. doi: 10.1093/ofid/ofad355. PMID: 37559753; PMCID: PMC10407246. 4: Cheruvu N, van Duijn E, Spigt PA, Barbu IM, Toussi SS, Schildknegt K, Jones RM, Obach RS. The Metabolism of Lufotrelvir, a Prodrug Investigated for the Treatment of SARS-COV2 in Humans Following Intravenous Administration. Drug Metab Dispos. 2023 Oct;51(10):1419-1427. doi: 10.1124/dmd.123.001416. Epub 2023 Jul 10. PMID: 37429728. 5: Bei ZC, Yu H, Wang H, Li Q, Wang B, Zhang D, Xu L, Zhao L, Dong S, Song Y. Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation. Emerg Microbes Infect. 2023 Dec;12(1):2211688. doi: 10.1080/22221751.2023.2211688. PMID: 37144395; PMCID: PMC10187092. 6: Zvornicanin SN, Shaqra AM, Huang QJ, Ornelas E, Moghe M, Knapp M, Moquin S, Dovala D, Schiffer CA, Kurt Yilmaz N. Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses. Viruses. 2023 Mar 18;15(3):781. doi: 10.3390/v15030781. PMID: 36992489; PMCID: PMC10059799. 7: Zinovjev K. Electrostatic Embedding of Machine Learning Potentials. J Chem Theory Comput. 2023 Mar 28;19(6):1888-1897. doi: 10.1021/acs.jctc.2c00914. Epub 2023 Feb 23. PMID: 36821513; PMCID: PMC10061678. 8: Lan S, Neilsen G, Slack RL, Cantara WA, Castaner AE, Lorson ZC, Lulkin N, Zhang H, Lee J, Cilento ME, Tedbury PR, Sarafianos SG. Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies. bioRxiv [Preprint]. 2023 Jan 3:2022.12.31.522389. doi: 10.1101/2022.12.31.522389. PMID: 36656782; PMCID: PMC9844013. 9: Jochmans D, Liu C, Donckers K, Stoycheva A, Boland S, Stevens SK, De Vita C, Vanmechelen B, Maes P, Trüeb B, Ebert N, Thiel V, De Jonghe S, Vangeel L, Bardiot D, Jekle A, Blatt LM, Beigelman L, Symons JA, Raboisson P, Chaltin P, Marchand A, Neyts J, Deval J, Vandyck K. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. mBio. 2023 Feb 28;14(1):e0281522. doi: 10.1128/mbio.02815-22. Epub 2023 Jan 10. PMID: 36625640; PMCID: PMC9973015. 10: Chen W, Shao Y, Peng X, Liang B, Xu J, Xing D. Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection. Front Pharmacol. 2022 Nov 11;13:1035969. doi: 10.3389/fphar.2022.1035969. PMID: 36438815; PMCID: PMC9691842. 11: Zhu T, Pawlak S, Toussi SS, Hackman F, Thompson K, Song W, Salageanu J, Winter E, Shi H, Winton J, Binks M. Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants. Clin Pharmacol Drug Dev. 2022 Dec;11(12):1382-1393. doi: 10.1002/cpdd.1174. Epub 2022 Oct 26. PMID: 36285536; PMCID: PMC9874748. 12: Heilmann E, Costacurta F, Geley S, Mogadashi SA, Volland A, Rupp B, Harris RS, von Laer D. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Commun Biol. 2022 Apr 27;5(1):391. doi: 10.1038/s42003-022-03277-0. PMID: 35478219; PMCID: PMC9046202. 13: Reina J, Iglesias C. Nirmatrelvir más ritonavir (Paxlovid) una potente combinación inhibidora de la proteasa 3CLpro del SARS-CoV-2 [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]. Rev Esp Quimioter. 2022 Jun;35(3):236-240. Spanish. doi: 10.37201/req/002.2022. Epub 2022 Feb 21. PMID: 35183067; PMCID: PMC9134883. 14: Zakharova MY, Kuznetsova AA, Uvarova VI, Fomina AD, Kozlovskaya LI, Kaliberda EN, Kurbatskaia IN, Smirnov IV, Bulygin AA, Knorre VD, Fedorova OS, Varnek A, Osolodkin DI, Ishmukhametov AA, Egorov AM, Gabibov AG, Kuznetsov NA. Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery. Front Pharmacol. 2021 Dec 6;12:773198. doi: 10.3389/fphar.2021.773198. PMID: 34938188; PMCID: PMC8686763. 15: Barazorda-Ccahuana HL, Nedyalkova M, Mas F, Madurga S. Unveiling the Effect of Low pH on the SARS-CoV-2 Main Protease by Molecular Dynamics Simulations. Polymers (Basel). 2021 Nov 5;13(21):3823. doi: 10.3390/polym13213823. PMID: 34771379; PMCID: PMC8587287. 16: Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O' Brien MN, O'Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rosales R, Rossulek MI, Sathish JG, Shirai N, Steppan C, Ticehurst M, Updyke LW, Weston S, Zhu Y, White KM, García-Sastre A, Wang J, Chatterjee AK, Mesecar AD, Frieman MB, Anderson AS, Allerton C. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat Commun. 2021 Oct 18;12(1):6055. doi: 10.1038/s41467-021-26239-2. PMID: 34663813; PMCID: PMC8523698. 17: Ramos-Guzmán CA, Ruiz-Pernía JJ, Tuñón I. Inhibition Mechanism of SARS-CoV-2 Main Protease with Ketone-Based Inhibitors Unveiled by Multiscale Simulations: Insights for Improved Designs*. Angew Chem Int Ed Engl. 2021 Dec 1;60(49):25933-25941. doi: 10.1002/anie.202110027. Epub 2021 Nov 3. PMID: 34581471; PMCID: PMC8653175. 18: Baig MH, Sharma T, Ahmad I, Abohashrh M, Alam MM, Dong JJ. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study. Molecules. 2021 Mar 17;26(6):1678. doi: 10.3390/molecules26061678. PMID: 33802860; PMCID: PMC8002701. 19: de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19. J Virol. 2021 Mar 10;95(7):e01819-20. doi: 10.1128/JVI.01819-20. Epub 2021 Feb 23. PMID: 33622961; PMCID: PMC8139662. 20: Liu C, Boland S, Scholle MD, Bardiot D, Marchand A, Chaltin P, Blatt LM, Beigelman L, Symons JA, Raboisson P, Gurard-Levin ZA, Vandyck K, Deval J. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development. Antiviral Res. 2021 Mar;187:105020. doi: 10.1016/j.antiviral.2021.105020. Epub 2021 Jan 27. PMID: 33515606; PMCID: PMC7839511.